NCT02019277 - A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 5, 2013

Primary Completion Date

November 4, 2016

Study Completion Date

November 4, 2016

Conditions

Breast Cancer

Interventions

DRUG

Docetaxel

Dosing regimen to be determined by the investigator, routine clinical practices.

DRUG

Nab-paclitaxel

Dosing regimen to be determined by the investigator, routine clinical practices.

DRUG

Paclitaxel

Dosing regimen to be determined by the investigator, routine clinical practices.

DRUG

Pertuzumab

Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.

DRUG

Trastuzumab

Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.

Trial Locations (13)

2217

St George Hospital; Cancer Care Centre, Kogarah

2298

Newcastle Mater Misericordiae Hospital; Oncology, Waratah

2444

Port Macquarie Base Hospital, Port Macquarie

3052

Royal Melbourne Hospital; Hematology and Medical Oncology, Parkville

3168

Monash Medical Centre; Oncology, Clayton

3220

Geelong Hospital; Andrew Love Cancer Centre, Geelong

3550

Bendigo Hospital; Oncology, Bendigo

4101

Mater Hospital; Cancer Services, South Brisbane

4102

Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba

5112

Lyell McEwin Hospital, Adelaide

6150

Fiona Stanley Hospital, Murdoch

St John of God Murdoch Hospital; Oncology West, Murdoch

7250

Launceston General Hospital, Launceston

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY